Patents by Inventor Sibylle DAMES

Sibylle DAMES has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acids for inhibiting expression of PROS1 in a cell
    Patent number: 11820971
    Abstract: The invention relates to nucleic acid products that interfere with or inhibit PROS1 gene expression. It further relates to therapeutic uses of PROS1 inhibition for the treatment of bleeding disorders.
    Type: Grant
    Filed: July 25, 2022
    Date of Patent: November 21, 2023
    Assignees: UNIVERSITÄT BERN, SILENCE THERAPEUTICS GMBH
    Inventors: Ute Schaeper, Sibylle Dames, Eliot Morrison, Raja Prince Eladnani, Anne Angelillo-Scherrer
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF CNNM4 IN A CELL
    Publication number: 20230265438
    Abstract: The invention relates to nucleic acid products that interfere with or inhibit CNNM4 (Cyclin M4) gene expression. It further relates to therapeutic uses of CNNM4 inhibition for the treatment of diseases, such as liver diseases including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver steatosis, liver fibrosis, liver cirrhosis, liver cancer and other diseases associated with magnesium dysregulation.
    Type: Application
    Filed: May 26, 2021
    Publication date: August 24, 2023
    Inventors: Ute SCHAEPER, Sibylle DAMES, Steffen SCHUBERT, Alfonso MARTÍNEZ DE LA CRUZ, Jorge SIMÓN ESPINOSA, Irene GONZALEZ RECIO, María Luz MARTÍNEZ CHANTAR
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF PROS1 IN A CELL
    Publication number: 20230019513
    Abstract: The invention relates to nucleic acid products that interfere with or inhibit PROS1 gene expression. It further relates to therapeutic uses of PROS1 inhibition for the treatment of bleeding disorders.
    Type: Application
    Filed: July 25, 2022
    Publication date: January 19, 2023
    Applicants: UNIVERSITÄT BERN, SILENCE THERAPEUTICS GMBH
    Inventors: Ute SCHAEPER, Sibylle DAMES, Eliot MORRISON, Raja PRINCE ELADNANI, Anne ANGELILLO-SCHERRER
  • Nucleic acids for inhibiting expression of LPA in a cell
    Patent number: 11499153
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the LPA gene expression or inhibit its expression, preferably for use as treatment, prevention or reduction of risk of suffering cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome linked to elevated levels of Lp(a) particles.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: November 15, 2022
    Assignee: SILENCE THERAPEUTICS GMBH
    Inventors: David Anthony Rider, Lucas Bethge, Christian Frauendorf, Adrien Weingärtner, Judith Hauptmann, Sibylle Dames, Steffen Schubert, Stephan Tenbaum
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL
    Publication number: 20220290144
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the LPA gene expression or inhibit its expression for use as treatment, prevention or reduction of risk of suffering cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome linked to elevated of Lp(a)-containing particles.
    Type: Application
    Filed: March 17, 2022
    Publication date: September 15, 2022
    Inventors: Sibylle Dames, Steffen Schubert, Stephan Tenbaum, Christian Frauendorf, Lucas Bethge, Judith Hauptmann, Adrien Weingartner, David Anthony Rider
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF PROS1 IN A CELL
    Publication number: 20220243202
    Abstract: The invention relates to nucleic acid products that interfere with PROS1 gene expression or inhibit its expression. The nucleic acids are particularly for use in the treatment, prevention or reduction of risk of suffering from a bleeding disorder.
    Type: Application
    Filed: May 6, 2020
    Publication date: August 4, 2022
    Applicants: UNIVERSITÄT BERN, SILENCE THERAPEUTICS GMBH
    Inventors: Sibylle DAMES, Ute SCHAEPER, Raja PRINCE ELADNANI, Anne ANGELILLO-SCHERRER
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL
    Publication number: 20220170016
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the LPA gene expression or inhibit its expression, preferably for use as treatment, prevention or reduction of risk of suffering cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome linked to elevated levels of Lp(a) particles.
    Type: Application
    Filed: December 22, 2021
    Publication date: June 2, 2022
    Inventors: David Anthony Rider, Lucas Bethge, Christian Frauendorf, Adrien Weingaertner, Judith Hauptmann, Sibylle Dames, Steffen Schubert, Stephan Tenbaum
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF PROS1 IN A CELL
    Publication number: 20220135974
    Abstract: The invention relates to nucleic acid products that interfere with or inhibit PROS1 gene expression. It further relates to therapeutic uses of PROS1 inhibition for the treatment of bleeding disorders.
    Type: Application
    Filed: November 11, 2021
    Publication date: May 5, 2022
    Applicants: UNIVERSITÄT BERN, SILENCE THERAPEUTICS GMBH
    Inventors: Ute SCHAEPER, Sibylle DAMES, Eliot MORRISON, Raja PRINCE ELADNANI, Anne ANGELILLO-SCHERRER
  • Nucleic acids for inhibiting expression of LPA in a cell
    Patent number: 11319537
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the LPA gene expression or inhibit its expression for use as treatment, prevention or reduction of risk of suffering cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome linked to elevated of Lp(a)-containing particles.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: May 3, 2022
    Assignee: SILENCE THERAPEUTICS GMBH
    Inventors: Sibylle Dames, Steffen Schubert, Stephan Tenbaum, Christian Frauendorf, Lucas Bethge, Judith Hauptmann, Adrien Weingärtner, David Anthony Rider
  • PRODUCTS AND COMPOSITIONS
    Publication number: 20220025377
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the TMPRSS6 gene expression or inhibits its expression and therapeutic uses such as for the treatment of hemochromatosis, porphyria and blood disorders such as ?-thalassemias, sickle cell disease and transfusional iron overload or myelodysplastic syndrome.
    Type: Application
    Filed: October 5, 2021
    Publication date: January 27, 2022
    Inventors: Sibylle DAMES, Ute Schaeper, Judith Hauptmann, Christian Frauendorf, Lucas Bethge, Adrien Weingärtner
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF C3 IN A CELL
    Publication number: 20220017899
    Abstract: The invention relates to nucleic acid products that interfere with complement component C3 gene expression or inhibit its expression. The nucleic acids are preferably for use as treatment, prevention or reduction of risk of suffering from complement component C3 associated diseases, disorders or syndromes, particularly C3 Glomerulopathy (C3G), Paroxysmal Nocturnal Hemoglobinuria (PNH), atypical Hemolytic Uremic Syndrome (aHUS), Lupus nephritis, IgA nephropathy (IgA N), Cold Agglutinin Disease (CAD), Myasthenia gravis (MG), and Primary Membranous Nephropathy.
    Type: Application
    Filed: November 22, 2019
    Publication date: January 20, 2022
    Inventors: Verena Aumiller, Sibylle Dames, Steffen Schubert, Judith Hauptmann, Christian Frauendorf, Marie Wikstrom Lindholm, Adrien Weingartner, Lucas Bethge
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL
    Publication number: 20220002722
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the LPA gene expression or inhibit its expression, preferably for use as treatment, prevention or reduction of risk of suffering cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome linked to elevated levels of Lp(a) particles.
    Type: Application
    Filed: November 13, 2019
    Publication date: January 6, 2022
    Inventors: David Anthony Rider, Lucas Bethge, Christian Frauendorf, Adrien Weingaertner, Judith Flauptmann, Sibylle Dames, Steffen Schubert, Stephan Tenbaum
  • Products and compositions
    Patent number: 11174483
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the TMPRSS6 gene expression or inhibits its expression and therapeutic uses such as for the treatment of hemochromatosis, porphyria and blood disorders such as ?-thalassemias, sickle cell disease and transfusional iron overload or myelodysplastic syndrome.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: November 16, 2021
    Assignee: Silence Therapeutics GmbH
    Inventors: Sibylle Dames, Ute Schaeper, Judith Hauptmann, Christian Frauendorf, Lucas Bethge, Adrien Weingärtner
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL
    Publication number: 20210123048
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the LPA gene expression or inhibit its expression for use as treatment, prevention or reduction of risk of suffering cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome linked to elevated of Lp(a)-containing particles.
    Type: Application
    Filed: November 13, 2018
    Publication date: April 29, 2021
    Inventors: Sibylle Dames, Steffen Schubert, Stephan Tenbaum, Christian Frauendorf, Lucas Bethge, Judith Hauptmann, Adrien Weingärtner, David Anthony Rider
  • PRODUCTS AND COMPOSITIONS
    Publication number: 20200208158
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the TMPRSS6 gene expression or inhibits its expression and therapeutic uses such as for the treatment of hemochromatosis, porphyria and blood disorders such as ?-thalassemias, sickle cell disease and transfusional iron overload or myelodysplastic syndrome.
    Type: Application
    Filed: April 5, 2018
    Publication date: July 2, 2020
    Applicant: Silence Therapeutics GmbH
    Inventors: Sibylle DAMES, Ute SCHAEPER, Judith HAUPTMANN, Christian FRAUENDORF, Lucas BETHGE, Adrien WEINGÄRTNER